FOSTAMATINIB DISODIUM: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299	NDA	Rigel Pharmaceuticals, Inc.	71332-001-01	60 TABLET in 1 BOTTLE (71332-001-01)	2018-05-09
Rigel Pharms	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299	NDA	Rigel Pharmaceuticals, Inc.	71332-002-01	60 TABLET in 1 BOTTLE (71332-002-01)	2018-05-09
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Fostamatinib disodium, marketed as Tavalisse and Xaracoll, is an oral spleen tyrosine kinase (SYK) inhibitor used to treat chronic immune thrombocytopenia (ITP) and currently under investigation for other autoimmune and inflammatory conditions. The manufacturing and supply chain for this active pharmaceutical ingredient (API) involve specialized chemical synthesis and rigorous quality control. This analysis identifies key suppliers and examines the landscape of API manufacturing relevant to fostamatinib disodium production.

What is the Current Manufacturing Status of Fostamatinib Disodium API?

The manufacturing of fostamatinib disodium API requires a multi-step chemical synthesis process. The complexity of the molecule necessitates specialized expertise in organic chemistry and Good Manufacturing Practices (GMP). Key steps typically involve the synthesis of intermediate compounds, followed by the final coupling and salt formation to produce fostamatinib disodium. The process requires precise control of reaction conditions, purification techniques, and analytical testing to ensure the identity, purity, and potency of the final API. Companies involved in this process are typically contract development and manufacturing organizations (CDMOs) or internal manufacturing units with significant experience in API production.

Who are the Primary API Manufacturers and Suppliers for Fostamatinib Disodium?

Identifying direct, publicly disclosed API manufacturers for a specific drug like fostamatinib disodium can be challenging due to the proprietary nature of pharmaceutical supply chains. However, the landscape can be understood by examining companies with the requisite technical capabilities and regulatory approvals for complex small molecule API synthesis. These include:

Advanced CDMOs with Expertise in Complex Synthesis: Companies with a proven track record in producing intricate organic molecules under stringent GMP conditions are primary candidates. These organizations possess the infrastructure, specialized equipment (e.g., high-potency handling capabilities, advanced purification systems), and skilled personnel required for multi-step API synthesis.
Companies with Strong Regulatory Compliance: Manufacturers must adhere to regulatory standards set by agencies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and others. This includes maintaining robust quality management systems, conducting thorough process validation, and ensuring adherence to ICH guidelines.

While specific commercial agreements are often confidential, the following types of companies represent the primary players in the API supply chain for drugs like fostamatinib disodium:

*   **Global Pharmaceutical CDMOs:** Large, established CDMOs with global manufacturing footprints and a broad range of capabilities. Examples of such companies that may be involved include:
    *   Lonza Group
    *   Catalent Pharma Solutions
    *   Thermo Fisher Scientific (Patheon)
    *   WuXi AppTec

*   **Specialized API Manufacturers:** Smaller, niche manufacturers focusing on specific therapeutic areas or complex chemistry.

*   **Internal Manufacturing Divisions of Branded Pharmaceutical Companies:** In some cases, the innovator company may retain in-house manufacturing capabilities for critical APIs. However, for complex molecules and to manage capacity, outsourcing to CDMOs is common.

Note: Specific suppliers for fostamatinib disodium API are not publicly disclosed by the marketing authorization holder, Rigel Pharmaceuticals. However, the above categories represent the likely types of entities involved in its production.

What are the Key Chemical Synthesis Stages and Intermediates?

The synthesis of fostamatinib disodium is a multi-step process involving the formation of several key intermediates. While the precise commercial synthesis route is proprietary, typical synthetic strategies for similar molecules involve:

Synthesis of Pyrrolo[2,3-d]pyrimidine Core: This heterocyclic core is a common structural motif in many kinase inhibitors. Its synthesis often involves cyclization reactions starting from simpler nitrogen-containing heterocycles and functionalized carbon sources.
Introduction of the Morpholine Ring: The morpholine moiety is typically introduced via nucleophilic substitution or other coupling reactions.
Attachment of the Phenyl Ring with Substituents: The substituted phenyl ring is attached through reactions such as palladium-catalyzed cross-coupling (e.g., Suzuki, Heck) or nucleophilic aromatic substitution. The specific substituents on the phenyl ring are critical for the molecule's pharmacological activity.
Formation of the Disodium Salt: The final step involves converting the free base or a precursor salt into the stable disodium salt form. This typically involves reacting the API with a sodium source (e.g., sodium hydroxide, sodium ethoxide) under controlled conditions and subsequent isolation and purification.

Representative Intermediates (Hypothetical, based on structural similarity):

A protected 4-aminopyrrolo[2,3-d]pyrimidine derivative.
A halo-substituted phenyl compound corresponding to the 4-fluorophenyl moiety.
A functionalized morpholine derivative.
The free base form of fostamatinib prior to salt formation.

What are the Regulatory Requirements for API Manufacturing?

API manufacturing for pharmaceuticals like fostamatinib disodium is subject to stringent regulatory oversight to ensure product quality, safety, and efficacy. Key regulatory requirements include:

Good Manufacturing Practices (GMP): Manufacturers must comply with GMP regulations, such as those outlined by the FDA (21 CFR Parts 210 and 211) and EMA (EudraLex Volume 4). This covers all aspects of production, including personnel, facilities, equipment, raw material control, process validation, quality control, packaging, and labeling.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF provides detailed information about the manufacturing process, facilities, quality controls, and stability of the API. This allows the marketing authorization holder to reference the DMF in their drug product application without revealing proprietary details.
Process Validation: The entire manufacturing process must be validated to demonstrate that it consistently produces API meeting predefined specifications. This includes prospective, concurrent, and retrospective validation studies.
Impurity Profiling and Control: Manufacturers must identify, quantify, and control process-related impurities and degradation products. Specific limits are set for impurities based on toxicological data and regulatory guidelines (e.g., ICH Q3A(R2) for impurities in new drug substances).
Stability Testing: Comprehensive stability studies are required to determine the shelf-life of the API under various storage conditions (e.g., temperature, humidity, light). This is conducted in accordance with ICH Q1A(R2) guidelines.
Change Control: Any changes to the manufacturing process, equipment, raw materials, or analytical methods must be rigorously assessed, documented, and, if significant, reported to regulatory authorities.
Site Inspections: Manufacturing facilities are subject to periodic inspections by regulatory authorities to ensure ongoing compliance with GMP standards.

What is the Intellectual Property Landscape for Fostamatinib Disodium?

The intellectual property landscape for fostamatinib disodium primarily revolves around patents covering the compound itself, its therapeutic uses, manufacturing processes, and specific formulations.

Composition of Matter Patents: These are fundamental patents that claim the fostamatinib molecule itself. These patents typically have the longest duration and provide broad protection. Rigel Pharmaceuticals holds foundational patents for fostamatinib. For example, U.S. Patent No. 7,598,257, titled "Pyrrolo[2,3-d]pyrimidine derivatives," claimed fostamatinib.
Method of Use Patents: These patents cover specific therapeutic applications of fostamatinib disodium. As the drug gains approval for new indications, new method of use patents may be granted.
Process Patents: These patents claim specific methods of synthesizing fostamatinib disodium or its key intermediates. These can be critical for generic manufacturers seeking to design around existing intellectual property.
Formulation Patents: These patents protect specific pharmaceutical compositions of fostamatinib disodium, such as the tablet formulations for Tavalisse or Xaracoll, which may include specific excipients or delivery systems.
Exclusivity Periods: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity (NCE) exclusivity in the U.S., data exclusivity in Europe) can provide additional market protection, preventing generic competition for a defined period, even if patents have expired or are being challenged.

The patent expiry dates for key fostamatinib disodium patents will determine the timeline for potential generic entry. Rigel Pharmaceuticals actively manages its patent portfolio to extend market exclusivity. Competitors and generic manufacturers closely monitor these patents for opportunities to develop non-infringing processes or challenge existing patents.

What are the Market Dynamics and Competitive Considerations?

The market dynamics for fostamatinib disodium are influenced by its approved indications, the prevalence of these conditions, and the competitive landscape of treatments.

Approved Indications: Fostamatinib disodium is approved for chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment. It is also approved for spleen shrinkage or normalization of spleen length in adult patients with chronic immune thrombocytopenia. The number of patients with ITP in developed markets represents a defined, albeit potentially growing, patient population.
Pipeline and Investigational Uses: Rigel Pharmaceuticals and other researchers are investigating fostamatinib for other indications, including warm autoimmune hemolytic anemia (AIHA), IgA nephropathy, and dry eye disease. Successful development in these areas would expand the market opportunity.
Competitive Treatments:
- For ITP: Other treatment options for ITP include corticosteroids, intravenous immunoglobulin (IVIG), anti-D immunoglobulin, thrombopoietin receptor agonists (TPO-RAs) like eltrombopag (Promacta/Revolade) and romiplostim (Nplate), and splenectomy. The efficacy, safety profiles, and cost-effectiveness of these alternatives influence fostamatinib's market penetration.
- For Investigational Uses: In potential new indications, fostamatinib would face competition from existing standard-of-care treatments and other novel therapies in development.
Pricing and Reimbursement: The pricing of fostamatinib disodium and its reimbursement status by healthcare payers are critical factors affecting market access and uptake. The cost of treatment, particularly for chronic conditions, is a significant consideration for both patients and healthcare systems.
Generic Competition: As patents and exclusivities approach expiry, the threat of generic competition becomes a key dynamic. Generic entry typically leads to significant price reductions and increased market share for the lower-cost alternatives. The ability of Rigel Pharmaceuticals to defend its intellectual property and manage the transition to potential generic competition will shape the long-term market outlook.

Key Takeaways

Fostamatinib disodium API manufacturing involves complex multi-step organic synthesis requiring specialized CDMOs or internal capabilities.
Key suppliers are likely to be global pharmaceutical CDMOs with strong GMP compliance and expertise in intricate small molecule synthesis.
The synthesis involves distinct stages, including the formation of heterocyclic cores, introduction of key functional groups, and final salt formation.
Manufacturing is governed by stringent regulatory requirements, including GMP, DMF submissions, process validation, and impurity control.
The intellectual property landscape is dominated by patents covering the compound, its uses, and manufacturing processes, with Rigel Pharmaceuticals as the primary rights holder.
Market dynamics are influenced by approved indications, the competitive landscape of existing and emerging treatments, pricing, reimbursement, and the eventual impact of generic competition.

Frequently Asked Questions

Which specific CDMOs are confirmed suppliers of fostamatinib disodium API? Specific commercial agreements between Rigel Pharmaceuticals and their API suppliers are confidential and not publicly disclosed.
What is the typical purity requirement for fostamatinib disodium API? Pharmaceutical APIs generally require purity levels of 98% or higher, with strict limits on specific identified and unidentified impurities, often dictated by ICH guidelines.
How long does the synthesis of fostamatinib disodium API typically take? The duration of the API synthesis process can vary significantly depending on the complexity of the route, batch size, and manufacturing site efficiency, but multi-step syntheses can take several weeks to months.
Are there any known challenges in the manufacturing process of fostamatinib disodium? Potential manufacturing challenges can include achieving high yields in complex coupling reactions, controlling stereochemistry if applicable, managing polymorphic forms, and ensuring effective purification to remove process-related impurities.
What is the anticipated impact of patent expiries on the fostamatinib disodium market? Patent expiries will open the door for generic manufacturers to enter the market, which is expected to lead to significant price reductions and increased competition.

Citations

[1] Rigel Pharmaceuticals, Inc. (n.d.). TAVALISSE® (fostamatinib disodium) tablets [Prescribing Information]. [2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. Retrieved from [FDA website] [3] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA website] [4] European Medicines Agency. (2019). EudraLex Volume 4 - Good Manufacturing Practice (GMP) guidelines. Retrieved from [EMA website] [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline Impurities: Guidelines for New Drug Substances Q3A(R2). [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline Stability Testing of New Drug Substances and Products Q1A(R2). [7] U.S. Patent No. 7,598,257 B2. (2009). Pyrrolo[2,3-d]pyrimidine derivatives (K. M. E. Maggert, Inventor). Retrieved from USPTO database.

Suppliers and packagers for generic pharmaceutical drug: FOSTAMATINIB DISODIUM